Related Experiment Video
Updated: Jun 5, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Long-term daclizumab therapy in relapsing-remitting multiple sclerosis
Monica A Rojas1, Noel G Carlson, Thomas L Miller
1Neurovirology Research Laboratory, VASLCHCS and Department of Neurology, University of Utah, Salt Lake City, UT, USA.
Abstract:
We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant reduction in relapse rate and improvement in Expanded Disability Status Scores (EDSSs) (p < 0.0001). Long-term treatment with daclizumab in RR MS patients has apparent benefit that will require formal confirmation.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Multiple Sclerosis l: Introduction
Drug Accumulation During Multiple Dosing: Repetitive IV Injections